BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hattangadi JA, Hong TS, Yeap BY, Mamon HJ. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer. 2009;115:3640-3650. [PMID: 19514088 DOI: 10.1002/cncr.24410] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 789] [Article Influence: 137.7] [Reference Citation Analysis]
2 Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys 2014;89:830-8. [PMID: 24867540 DOI: 10.1016/j.ijrobp.2014.03.034] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
3 Matsuzawa F, Kamachi H, Mizukami T, Einama T, Kawamata F, Fujii Y, Fukai M, Kobayashi N, Hatanaka Y, Taketomi A. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells. BMC Cancer 2021;21:200. [PMID: 33637083 DOI: 10.1186/s12885-020-07722-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Tanaka M, Mihaljevic AL, Probst P, Heckler M, Klaiber U, Heger U, Büchler MW, Hackert T. Meta-analysis of recurrence pattern after resection for pancreatic cancer. British Journal of Surgery 2019;106:1590-601. [DOI: 10.1002/bjs.11295] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 22.5] [Reference Citation Analysis]
5 Schoellhammer HF, Goldner BS, Kim J, Singh G. Beyond the whipple operation: radical resections for cancers of the head of the pancreas. Indian J Surg Oncol 2015;6:41-6. [PMID: 25937763 DOI: 10.1007/s13193-013-0258-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Kristensen A, Vagnildhaug OM, Grønberg BH, Kaasa S, Laird B, Solheim TS. Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. Crit Rev Oncol Hematol 2016;99:286-98. [PMID: 26819138 DOI: 10.1016/j.critrevonc.2016.01.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
7 Okui N, Kamata Y, Sagawa Y, Kuhara A, Hayashi K, Uwagawa T, Homma S, Yanaga K. Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer. Pancreatology 2019;19:88-96. [PMID: 30416041 DOI: 10.1016/j.pan.2018.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yovino S, Maidment BW 3rd, Herman JM, Pandya N, Goloubeva O, Wolfgang C, Schulick R, Laheru D, Hanna N, Alexander R, Regine WF. Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys 2012;83:916-20. [PMID: 22284684 DOI: 10.1016/j.ijrobp.2011.08.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
9 Hitchcock KE, Nichols RC, Morris CG, Bose D, Hughes SJ, Stauffer JA, Celinski SA, Johnson EA, Zaiden RA, Mendenhall NP, Rutenberg MS. Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. World J Gastrointest Surg. 2017;9:103-108. [PMID: 28503258 DOI: 10.4240/wjgs.v9.i4.103] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kumar AMS, Falk GA, Pelley R, Walsh RM, Abdel-wahab M. Adjuvant chemoradiation may improve survival over adjuvant chemotherapy in resected pancreatic cancer patients who are high risk for locoregional recurrence. J Radiat Oncol 2015;4:271-6. [DOI: 10.1007/s13566-015-0186-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Colloca G, Venturino A, Guarneri D. Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer. Clin Colorectal Cancer 2016;15:264-76. [PMID: 26776098 DOI: 10.1016/j.clcc.2015.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ 3rd, Hogg ME. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Ann Surg Oncol. 2018;25:3483-3491. [PMID: 29786131 DOI: 10.1245/s10434-018-6521-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
13 Verma V, Li J, Lin C. Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications. Am J Clin Oncol. 2016;39:302-313. [PMID: 26950464 DOI: 10.1097/coc.0000000000000278] [Cited by in Crossref: 52] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
14 Bissolati M, Sandri MT, Burtulo G, Zorzino L, Balzano G, Braga M. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. Tumor Biol 2015;36:991-6. [DOI: 10.1007/s13277-014-2716-0] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 9.1] [Reference Citation Analysis]
15 Nichols RC, Rutenberg M. Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons. World J Gastrointest Surg. 2019;11:303-307. [PMID: 31602289 DOI: 10.4240/wjgs.v11.i7.303] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Colbert LE, Moningi S, Chadha A, Amer A, Lee Y, Wolff RA, Varadhachary G, Fleming J, Katz M, Das P, Krishnan S, Koay EJ, Park P, Crane CH, Taniguchi CM. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol 2017;2:403-15. [PMID: 29114609 DOI: 10.1016/j.adro.2017.02.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
17 Nichols RC, Huh S, Li Z, Rutenberg M. Proton therapy for pancreatic cancer. World J Gastrointest Oncol 2015;7:141-7. [PMID: 26380057 DOI: 10.4251/wjgo.v7.i9.141] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
18 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 650] [Article Influence: 80.0] [Reference Citation Analysis]
19 Appel BL, Tolat P, Evans DB, Tsai S. Current Staging Systems for Pancreatic Cancer. The Cancer Journal 2012;18:539-49. [DOI: 10.1097/ppo.0b013e318278c5b5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
20 Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB (Oxford). 2014;16:34-39. [PMID: 23458131 DOI: 10.1111/hpb.12058] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
21 Ma N, Wang Z, Zhao J, Long J, Xu J, Ren Z, Jiang G. Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy. Med Sci Monit 2017;23:2315-23. [PMID: 28512284 DOI: 10.12659/msm.904393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
22 Sheffield KM, Crowell KT, Lin YL, Djukom C, Goodwin JS, Riall TS. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol 2012;19:1670-7. [PMID: 22143577 DOI: 10.1245/s10434-011-2152-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
23 Horowitz DP, Hsu CC, Wang J, Makary MA, Winter JM, Robinson R, Schulick RD, Cameron JL, Pawlik TM, Herman JM. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2011;80:1391-1397. [PMID: 20643511 DOI: 10.1016/j.ijrobp.2010.04.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
24 Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, Fishman E, Hruban RH, Herman JM, Laheru D, Weiss M, Li M, De Jesus-Acosta A, Wolfgang CL, Zheng L. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget 2015;6:36903-10. [PMID: 26372811 DOI: 10.18632/oncotarget.5054] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
25 Qiu Y, Shimada K, Hiraoka N, Maeshiro K, Ching WK, Aoki-Kinoshita KF, Furuta K. Knowledge discovery for pancreatic cancer using inductive logic programming. IET Syst Biol 2014;8:162-8. [PMID: 25075529 DOI: 10.1049/iet-syb.2013.0044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
26 Kim HW, Lee J, Paik K, Kang J, Kim YH, Yoon Y, Han H, Kim J, Hwang J. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Surgery 2017;161:1579-87. [DOI: 10.1016/j.surg.2016.12.038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
27 Kim BH, Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Joo I, Ha SW. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Cancer Res Treat 2015;47:274-81. [PMID: 25544574 DOI: 10.4143/crt.2014.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
28 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Reference Citation Analysis]
29 Hong TS, Ryan DP, Blaszkowsky LS, Mamon HJ, Kwak EL, Mino-Kenudson M, Adams J, Yeap B, Winrich B, DeLaney TF. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys. 2011;79:151-157. [PMID: 20421151 DOI: 10.1016/j.ijrobp.2009.10.061] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
30 Downs-Canner S, Zenati M, Boone BA, Varley PR, Steve J, Hogg ME, Zureikat A, Zeh HJ, Lee KK. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. J Surg Oncol 2015;112:80-5. [PMID: 26153355 DOI: 10.1002/jso.23943] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
31 Sato K, Mori R, Hiroshima Y, Oba MS, Matsuyama R, Bouvet M, Hoffman RM, Endo I. RT-PCR of peritoneal washings predicts peritoneal pancreatic cancer recurrence. J Surg Res 2018;226:122-30. [PMID: 29661277 DOI: 10.1016/j.jss.2017.11.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-bourgade S, Bellera C, Mathoulin-pélissier S, Collette L. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer 2014;50:2983-93. [DOI: 10.1016/j.ejca.2014.07.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
33 Gupta N, Yelamanchi R. Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management. World J Gastroenterol 2021;27:3158-81. [PMID: 34163104 DOI: 10.3748/wjg.v27.i23.3158] [Reference Citation Analysis]
34 Wang L, Dong P, Wang W, Li M, Hu W, Liu X, Tian B. Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2020;99:e19504. [PMID: 32176094 DOI: 10.1097/md.0000000000019504] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Hoffe S, Rao N, Shridhar R. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation. Semin Radiat Oncol 2014;24:113-25. [PMID: 24635868 DOI: 10.1016/j.semradonc.2013.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
36 Fujii Y, Kamachi H, Matsuzawa F, Mizukami T, Kobayashi N, Fukai M, Taketomi A. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model. Invest New Drugs 2021. [PMID: 33905019 DOI: 10.1007/s10637-021-01118-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wo JY, Childs SK, Szymonifka J, Mamon HJ, Ryan DP, Blaszkowsky LS, Kwak EL, Ferrone CR, Allen JN, Zhu AX, Wolpin BM, Chan JA, Abrams TA, McCleary NJ, Fernandez-Del Castillo C, Hong TS. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Pract Radiat Oncol 2014;4:e117-23. [PMID: 24890357 DOI: 10.1016/j.prro.2013.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
38 Strippoli A, Rossi S, Martini M, Basso M, D'Argento E, Schinzari G, Barile R, Cassano A, Barone C. ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. Oncotarget 2016;7:35159-68. [PMID: 27147577 DOI: 10.18632/oncotarget.9063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
39 Habermehl D, Brecht IC, Bergmann F, Rieken S, Werner J, Büchler MW, Springfeld C, Jäger D, Debus J, Combs SE. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World J Surg Oncol 2015;13:149. [PMID: 25889749 DOI: 10.1186/s12957-015-0560-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys 2011;80:1383-90. [PMID: 20708856 DOI: 10.1016/j.ijrobp.2010.04.058] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]